TrialJournal of neuromuscular diseases2021

Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial.

Craig M McDonald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.